Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Health-Related QoL Poor Among Myeloma, Pancreatic Cancer Survivors

November 11, 2014
By Leah Lawrence
Article

Survivors of multiple myeloma and pancreatic cancer may have some of the poorest physical health-related quality of life outcomes, according to a new study.

Although researched less, survivors of cancers that occurred at less common sites may also have poor health-related quality of life (HRQOL) outcomes, particularly among survivors of multiple myeloma and pancreatic cancer.

Erin E. Kent, PhD, of the National Cancer Institute, and colleagues used data from the Surveillance, Epidemiology, and End Results (SEER) national cancer registry system and the Medicare Health Outcomes Survey (MHOS) to research HRQOL in more than 16,000 cancer survivors.

“Most studies of HRQOL among cancer patients and survivors have been limited to breast cancer and, to a lesser extent, prostate, colorectal, and lung cancer, and even fewer studies have examined HRQOL among older long-term survivors,” Kent and colleagues wrote in Cancer. “However, much less is known about the HRQOL experiences of individuals with one of the less common malignancies.”

Therefore, in this study, the researchers looked at patients with kidney cancer, bladder cancer, pancreatic cancer, upper gastrointestinal cancer, cancer of the oral cavity and pharynx, uterine cancer, cervical cancer, thyroid cancer, melanoma, chronic leukemia, non-Hodgkin lymphoma, and multiple myeloma. Outcomes of the 36-Item Short Form Health Survey and the Veterans RAND 12-Item Health Survey were examined and compared to individuals without cancer.

Overall, cancer survivors had lower average Physical Component Scores (PCS) than did individuals without cancer. However, Mental Component Scores (MCS) did not greatly differ between the two groups. A utility metric (Short Form 6D/Veterans RAND 6D), which adjusted for chronic conditions and sociodemographic characteristics, was also calculated.

The lowest PCS and MCS scores reported were among survivors of multiple myeloma (31.3 and 48.8) and pancreatic cancer (35.3 and 48). Survivors of multiple myeloma also had the lowest mean Short Form 6D/Veterans RAND 6D score of 0.63, which was 0.10 points different from individuals without cancer.

Bodily pain, Role-Physical, and Vitality were all prominent concerns among survivors of pancreatic cancer and myeloma, with these two cancer type survivors reporting the lowest mean scores for Role-Physical.

“The disease burden, as evidenced by the current study and a few other published reports of multiple myeloma and pancreatic cancer, suggests the need for research to identify factors that contribute to inferior outcomes among respondents with these malignancies,” the researchers wrote.

In addition, the researchers noted that further research was needed in patients with even less common cancers, such as liver cancer, who were not well-represented in the SEER-MHOS databases.

Recent Videos
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
Related Content
Advertisement

In unweighted analyses, significant PFS improvements were observed, highlighting the differences in restricted mean survival time of 6.95 months.

Elranatamab and MagnetisMM-3 Results are Superior to Real-World Multiple Myeloma Outcomes

Tim Cortese
August 24th 2025
Article

An observational study reported that results with elranatamab for patients with RRMM from the MagnetisMM-3 trial were superior to what was observed across 5 centers in the UK.


A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.


Another analysis excluded 7 trials that evaluated neoadjuvant radiation alone in historical cohorts and still found that pCR was not correlated with OS or DFS.

pCR Does Not Correlate With Survival in Rectal Cancer

Tim Cortese
August 23rd 2025
Article

A meta-analysis did not find any correlation between pathologic complete response and overall survival or disease-free survival in patients with rectal cancer.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Significantly improved survival was observed with oxaliplatin among patients 60 to 70 years of age with stage III CRC, but not those older than 70 years.

Oxaliplatin Elicits Improved Survival in Select Patients with Stage III CRC

Roman Fabbricatore
August 22nd 2025
Article

Significantly improved survival was observed with oxaliplatin among patients 60 to 70 years of age with stage III CRC, but not those older than 70 years.


Previously, TTFields was granted approval by the FDA in previously treated metastatic NSCLC.

Developer Submits Premarket Approval Application for TTFields in Pancreatic Cancer

Tim Cortese
August 21st 2025
Article

TTFields plus chemotherapy significantly prolonged overall survival compared with chemotherapy alone in patients with pancreatic cancer.

Related Content
Advertisement

In unweighted analyses, significant PFS improvements were observed, highlighting the differences in restricted mean survival time of 6.95 months.

Elranatamab and MagnetisMM-3 Results are Superior to Real-World Multiple Myeloma Outcomes

Tim Cortese
August 24th 2025
Article

An observational study reported that results with elranatamab for patients with RRMM from the MagnetisMM-3 trial were superior to what was observed across 5 centers in the UK.


A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.


Another analysis excluded 7 trials that evaluated neoadjuvant radiation alone in historical cohorts and still found that pCR was not correlated with OS or DFS.

pCR Does Not Correlate With Survival in Rectal Cancer

Tim Cortese
August 23rd 2025
Article

A meta-analysis did not find any correlation between pathologic complete response and overall survival or disease-free survival in patients with rectal cancer.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Significantly improved survival was observed with oxaliplatin among patients 60 to 70 years of age with stage III CRC, but not those older than 70 years.

Oxaliplatin Elicits Improved Survival in Select Patients with Stage III CRC

Roman Fabbricatore
August 22nd 2025
Article

Significantly improved survival was observed with oxaliplatin among patients 60 to 70 years of age with stage III CRC, but not those older than 70 years.


Previously, TTFields was granted approval by the FDA in previously treated metastatic NSCLC.

Developer Submits Premarket Approval Application for TTFields in Pancreatic Cancer

Tim Cortese
August 21st 2025
Article

TTFields plus chemotherapy significantly prolonged overall survival compared with chemotherapy alone in patients with pancreatic cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.